Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Loss per Share

Note 7 - Loss per Share

6 Months Ended

Jun. 30, 2024

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 7 - Net Loss Per Share

Basic and diluted net loss per common share was calculated as follows:

		Three Months Ended June 30,								Six Months Ended June 30,
(in thousands, except for net loss per share)		*2024*				*2023*				*2024*				*2023*
Numerator:
Net loss		$	(1,715	)		$	(2,200	)		$	(3,357	)		$	(4,635	)

Denominator:
Weighted-average common shares outstanding, basic and diluted			17,515				13,420				16,747				13,264

Net loss per common share, basic and diluted		$	(0.10	)		$	(0.16	)		$	(0.20	)		$	(0.35	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share
Stock options to purchase common stock			2,104				2,114				2,104				2,114
Unvested restricted stock units			349				526				349				526